Legal Representation
Attorney
Brian A. Tollefson
USPTO Deadlines
Next Deadline
977 days remaining
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2018-04-10)
Due Date
April 10, 2028
Grace Period Ends
October 10, 2028
Application History
46 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Jun 6, 2025 | PR75 | O | POST REGISTRATION ACTION MAILED - SEC. 71 & 15 | Loading... |
May 15, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
May 15, 2025 | EROP | I | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | Loading... |
May 15, 2025 | EWOR | I | TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED | Loading... |
May 15, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
May 15, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
Dec 16, 2024 | PR75 | O | POST REGISTRATION ACTION MAILED - SEC. 71 & 15 | Loading... |
Nov 20, 2024 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
Apr 9, 2024 | ES75 | I | TEAS SECTION 71 & 15 RECEIVED | Loading... |
Apr 10, 2023 | REM3 | E | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | Loading... |
Oct 24, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
Oct 24, 2022 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
Oct 24, 2022 | ECDR | I | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | Loading... |
Oct 24, 2022 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
Oct 24, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
Oct 24, 2022 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
Oct 24, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
Apr 9, 2021 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
Aug 11, 2018 | FINV | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
Jul 16, 2018 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
Jul 16, 2018 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
Jul 10, 2018 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
Apr 10, 2018 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
Feb 22, 2018 | ADCH | M | CHANGE OF NAME/ADDRESS REC'D FROM IB | Loading... |
Feb 10, 2018 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
Jan 23, 2018 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Jan 23, 2018 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Jan 3, 2018 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
Jan 3, 2018 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
Jan 3, 2018 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Dec 11, 2017 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Dec 11, 2017 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Dec 11, 2017 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Dec 11, 2017 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Oct 20, 2017 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
Oct 20, 2017 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
Aug 4, 2017 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
Jul 18, 2017 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
Jul 18, 2017 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
Jul 12, 2017 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
Jul 12, 2017 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
Jul 11, 2017 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Jul 8, 2017 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Jul 8, 2017 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Jul 7, 2017 | LIMI | I | LIMITATION FROM ORIGINAL APPLICATION ENTERED | Loading... |
Jul 6, 2017 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceutical [ and veterinary ] preparations, namely, [ recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues ] for use in human [ and veterinary ] medicine; chemical preparations for pharmaceutical or medical purposes, namely, [ recombinant therapeutic proteins, ] nucleic acids, [ peptides, cells, genes and tissues ] for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco skeletal, metabolic diseases, dermatology; prescription and non-prescription ] medicines, namely, [ pills, tablets, capsules, caplets, liquid drops, sachets, syringes, infusion bags, ] vials and pharmaceutical preparations for the treatment of disorders in the field of cancer, immunology [ , heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology ] ; biological preparations for the treatment of disorders in the field of cancer, immunology [ , heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology ] ; biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancer, immunology, [ heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; chemical preparations for pharmaceutical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical and veterinary purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use, namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes ] ; biological reagents for medical use; medicinal products based on cells and genes, namely, [ somatic cells, ] genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical [ and veterinary ] purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; [ biological reagents for medical use; medicinal products based on cells and genes, namely, somatic cells, genetically modified cells, viral vectors, nucleic acids and engineered tissues; products for somatic cell therapy, namely, adult stem cells, t-cells, b-cells, nk cells, dendritic cells, monocytes, macrophages, adipocytes, keratinocytes, erythrocytes, platelets, ] products for gene therapy, namely, [ genetically modified cells, viral vectors, ] nucleic acids; [ tissue engineered products, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace or restore a lost or impaired tissue or function; ] [ products for regenerative medicine, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace, restore or promote the repair, replacement or regeneration of a lost or impaired tissue or function; ] products for personalized medicine made of [ autologous cells or proteins or ] nucleid acids derived from individual genomic sequences; [ preparations made up of cells for medical or clinical use; ] preparations made up of nucleic acids, namely, nucleic acid sequences and chemical reagents for medical purposes [ ; preparations made up of tissues, namely, biological tissue cultures for medical purposes; vaccines; recombinant proteins supplements; therapeutic kits consisting of therapeutic antibodies, buffers, and reagents for use in disease treatment and therapy ]
Class 042
Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; research and development in the pharmaceutical and biotechnology fields; research and development in the field of micro-organisms and cells; research and development in biochemistry; scientific research and development in biology; research and development in the field of diagnostic preparations; services of medical laboratories; medical information and data on research and development in the medical and veterinary fields; scientific and technological services, namely, scientific research and, literature scientific research in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology, consultancy to ensure compliance with quality standards, the design and validation of manufacturing processes
Additional Information
Design Mark
The mark consists of the following: the stylized term "ANEMOCYTE" with the letters "ANEM" and "YTE" appearing in dark grey, and the letters "OC" merged and appearing in light blue, green, blue and light grey.
Color Claim
The color(s) light blue, green, blue, light grey and dark grey is/are claimed as a feature of the mark.
Classification
International Classes
005
042